CYP1A1 and breast carcinoma: Molecular modeling showed CYP1B1 favored a ring orientation to the heme group compared to CYP1A1; therefore, activation of CYP1B1 and conversion of luteolin to the hydroxylated form may enhance antiproliferative activity against breast cancer.